Purpose: This study aimed to evaluate the prognostic significance of smoking status in muscle invasive bladder cancer (MIBC) and non-MIBC in recurrence-free (RFS), progression-free (PFS), disease-free survival (DFS), and cancer-specific survival (CSS).
INTRODUCTION
Cigarette smoking is a strong risk factor for the development of bladder cancer (BC). For example, smoking accounts for approximately one-half of the BC risk among men and one-third of this risk among women, and smokers have a 2-4 fold higher risk of developing BC, compared to nonsmokers. Several studies have reported that smoking is associated with more invasiveness, more advanced stage and grade, higher recurrence and progression rates, shorter cancer-specific survival, and poorer therapeutic response among patients with BC. [2] [3] [4] [5] [6] [7] Furthermore, smoking is a prognostic factor for clinical outcomes from BC after transurethral resection of the bladder (TURB) and radical cystectomy (RC). 5, [8] [9] [10] However, other studies have reported conflicting effects of smoking on these previously confirmed prognostic effects that low-graded tumors were associated with the smoking. [11] [12] [13] Therefore, the present study was designed to evaluate the prognostic significance of smoking status among clinicopathological, immunohistochemical in muscle invasive (MIBC) and nonmuscle invasive BC (NMIBC) treated with surgery. Furthermore, the effect of smoking status on postsurgical outcomes and the expression of biomarkers in the BC tissues were also analyzed statistically.
MATERIALS AND METHODS

Ethical Considerations
This study was approved by the Institutional Review Board (IRB) of the National Cancer Center (approval number:
NCC-NCS-13-833), and conducted according to the principles expressed in the Declaration of Helsinki. The requirement for written informed consent by participant was waived, due to the retrospective design by the IRB. All patients' records/information was anonymized and deidentified prior to analysis.
Patient Population
We evaluated 541 patients with initially diagnosed BC who underwent TURB or RC with urinary diversion at the National ) and the duration and intensity of the smoking habit, which included the number of cigarette pack-years, the number of years of smoking, and the number of years since smoking cessation. The exposure variable was defined as pack-years, which was calculated as (cigarettes smoked per day/20) × (years smoked). The NS, FS, and CS groups were defined as patients who had never smoked or who had smoked ＜100 cigarettes during their lifetime, patients who quit smoking ≥1 year before their diagnosis, and patients who still smoked regularly (＞100 cigarettes) at the time of diagnosis, respectively. However, no information regarding smoking style, product brand, and degree of inhalation were obtained.
TURB and Intravesical Instillation Therapy
All patients with proven primary urothelial carcinoma of the and no medical follow-up data after the RC.
Follow-up and Subsequent Treatment
After treatment with TURB, RC, or partial cystectomy, patients were generally followed-up according to the guideline's recommendations. 18, 19 In cases of TURB for NMIBC, disease recurrence was defined as the first tumor recurrence in the bladder, regardless of tumor stage, and progression was defined as any tumor recurrence at stage T2 or higher in the bladder. The tumor was resected when disease recurrence was detected.
When disease recurrence was not detected but the urine cytology results were positive, the patients underwent bladder and prostatic urethra biopsies in addition to an upper urinary tract workup. In cases of RC or partial cystectomy for MIBC, recurrence was defined as local recurrence in the pelvic cavity or distant metastasis that was confirmed using imaging and biopsy (if indicated). In cases of death, the cause of death was determined by the treating physicians, by a chart review that was corroborated by the death certificate, or by the death certificate alone. Tumor recurrence in the upper urinary tract was not considered tumor recurrence, but rather as a second primary Loss of PTEN was considered present when ＞50% of the cells exhibited negative cytoplasmic staining.
Statistical Analysis
Baseline characteristics were evaluated using the chi-square 
RESULTS
Among the 534 patients, we identified 441 patients (82.6%) with NMIBC and 93 patients (17.4%) with MIBC patients.
These patients included 160 NS (30%), 176 FS (33%), and 198 CS (37%). When we compared the CS, FS, and NS groups, we did not observe any significant differences in their pathological staging, grades, and immunohistological findings ( Table   1 ). The median smoking duration was 30 years (range, 5-65 years) for FS, and 42 years (range, 5-66 years) for CS. The smoking amounts were 26 pack-years (range, 2.5-100 pack/yr) for FS, and 37.0 pack-years (range, 2.5-110 pack-years) for CS.
Among the 441 patients with NMIBC, the significant risk factor for recurrence was pathologic tumor size (1- Table 3 ). The log-rank test was used to compare the Kaplan-Meier survival curves, and revealed significantly different CSS according to smoking status (p＜0.05), although no differences were observed for DFS (Fig. 2, Table 3 , Supplementary Table 6 ).
DISCUSSION
Cigarette smoking has known a leading cause of BC, due to the production of multiple carcinogenic substances that can induce sequential genetic and epigenetic changes and instabilities in the urothelium. 21, 22 These substances are cleared via excretion through the bladder, which leads to a risk of urothelial carcinoma that increases in proportion to the duration of exposure to these carcinogens in the urine. 23 tigated the relationship of smoking status with BC incidence and mortality, and found that CS exhibited a higher incidence and mortality in both sexes, although these factors were not affected by the amount and duration of smoking. 20 Another
Korean study of 156 patients with BC investigated the effect of smoking on RFS and PFS in BC, and found no significant differences in the stages and grades among the CS, FS, and NS. Nevertheless, the authors reported a significant difference in the recurrence rate between the FS and NS groups (p ＜0.05).
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In the present study, we did not observed any differences in important end points in the management of NMIBC. [6] [7] [8] 11, 12 However, in this study, any significant differences in RFS and PFS were observed according to smoking status, although CS exhibited a significantly improved CSS. The absence of a significant association between smoking status and RFS in NMIBC might be due to IVT obscuring any differences in recurrence or mortality, as it significantly affected PFS and CSS in this study. 26, 27 Some reports have also suggested that smoking affects the efficacy of IVT and BCG by reducing cytokine activity, B-and T-cell responses, and natural killer cell activation. 28, 29 However, one recent study did not find that smoking affected BCG response, 29 and the present study's results also indicate that the efficacy of IVT in NMIBC was independently able to prevent disease progression to MIBC.
Another reason for the insignificant association between smoking status and BC prognosis might be that the influence of smoking status on recurrence was more relevant among high-risk patients during a long-term follow-up. However, this study did not classify the patients into risk groups, and the median follow-up time was not only 4 years not enough long to expect the prognostic influences of smoking status in BC.
Therefore, longer follow-up and classification according to risk may be necessary to detect differences in recurrence according to smoking status.
Given the hypothetical interaction between carcinogens in the urine and detrimental genetic changes throughout the urothelium, it is possible that RC is an important prognostic factor in patients with MIBC. In this context, RC might result in complete removal of the damaged urothelial cells and elimination of carcinogen exposure, due to the urinary diversion.
Several clinical studies also support the hypothesis that smokers with BC experience lower rates of new tumor occurrence, and worse survival and mortality outcomes, after urinary diversion procedures. 9 Another Korean study found that NS tended to have poorer RFS, although there was no association between smoking and BC prognosis after RC, 11 similar to this study reporting smoking status not an independent risk factor for DFS in MIBC.
Lastly, the association between the expression of various common biomarkers (p53, Rb, PTEN, Bcl-2, and Ki-67) and disease recurrence or progression according to smoking status has been evaluated that any statistically significant associations were found in this study. In contrast, a recent study used similar biomarkers (p53, p21, pRb, and p27) found that smoking was a significant prognostic factor in BC, and that these biomarkers predicted recurrence and mortality according to smoking status. 30 This discrepancy may be related to different methodologies in these studies.
This study contained several important limitations that warrant consideration such as a nonrandomized retrospective design with relatively short follow-up, and a possible recall bias from the self-reported smoking data. Further absence of considerations were also limited factors of this study about the patients' comorbidities, smoking habits (amount, duration, and time since cessation), forms of cigarette products, the effect of different intravesical chemotherapy and BCG agents. In addition, further consideration about the risk stratification including stage and grade might be helpful to explain the relationship between the smoking and the prognoses in patients with BC.
Therefore, a larger prospective study with a long-term follow-up, as well as biochemical verification of smoking and hormonal status, is needed to identify sex-related differences and compensate for these limitations.
CONCLUSIONS
In the present study, no statistically significant differences of poor prognoses were observed according to smoking status among the patients' clinicopathological and prognostic characteristics in BC. Further larger prospective study with a long-term follow-up would be needed for the prognostic effect of smoking status in BC.
